This article originally published on The Limbic Most parents of children undergoing active cancer treatment at the RCH Children’s Cancer Centre, Melbourne last year reported no change to their child’s care due to COVID-19. An online survey of more than 100 parents in October-November 2020 found 69% reported no change to their child’s treatment plan...Continue Reading
Pomalidomide (Pomalyst) in combination with bortezomib and dexamethasone (PVd) will be reimbursed on the PBS from 1 October for patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. According to distributor Bristol Myers Squibb, the thalidomide analogue was approved based on findings from the OPTIMISMM trial...Continue Reading
People with blood cancers who are immunocompromised are now advised to have a third primary dose of COVID-19 vaccine with an mRNA vaccine. On 8 October the Australian Technical Advisory Group on Immunisation (ATAGI) recommended a booster third dose of vaccine as part of the primary course in individuals who are severely immunocompromised to address the risk...Continue Reading
This article was originally posted on Stuff Around 21,000 Kiwis are living with blood cancer. Symptoms can be difficult to recognise, and experts worry that some people aren’t getting diagnosed as our health system tackles the impact of Covid-19. Hayley McLarin investigates. Neil Brownlie has beaten blood cancer three times in a decade. The former...Continue Reading
Welcome to issue 39 of Multiple Myeloma Research Review. This issue’s selection includes research reporting that switching elderly intermediate-fit patients with MM to reduced-dose lenalidomide maintenance without dexamethasone after nine cycles of Rd was both feasible and provided outcomes similar to those associated with continuing Rd. As usual we have attached the PDF, and now...Continue Reading
Dear AllWe are now certainly in the grip of a cold winter with many parts of the country experiencing significant snow conditions. I imagine that most of you will have had at least your first vaccination by now. There is some data that shows that myeloma patients are having sub optimal responses to the Pfizer...Continue Reading
CANCELLED – date to be reviewed in 2022 At this stage the Myeloma National Patient Seminar due to be held on Saturday 13th November 2021 at the Intercontinental Wellington, 2 Grey Street, Wellington, has been cancelled with a plan to review new dates in 2022. Subscribe to our newsletter for emailed updates.Continue Reading
This article was originally published on The Limbic Patients with blood cancer – including leukaemia, myeloma, and lymphoma – experience higher psychological distress from risk of COVID-19 infection and unmet needs, finds new research Over a year into the pandemic, we have all felt the effects at this point. But the disruptions and stress haven’t...Continue Reading
Patients with blood cancer – including leukaemia, myeloma, and lymphoma – experience higher psychological distress from risk of COVID-19 infection and unmet needs, finds new research Over a year into the pandemic, we have all felt the effects at this point. But the disruptions and stress haven’t been spread evenly across the population and the...Continue Reading
